The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid

Autor: Markus J. Schwarz, Henrik Zetterberg, Maren Leifheit-Nestler, Matthias Schmitz, Inga Zerr, Michael Neumaier, Natalie Moll, Cagakan Ozbalci, Alexander Sartorius, Laura Kranaster, Laura Bindila, Dieter Haffner, Sonani Mindt, Norbert Müller, Beat Lutz, Peter Zill, Carolin Hoyer, Kaj Blennow
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Oncology
Adult
Male
medicine.medical_specialty
Bipolar Disorder
Kynurenine pathway
cerebrospinal fluid [Depressive Disorder
Treatment-Resistant]
medicine.medical_treatment
Depressive Disorder
Treatment-Resistant
03 medical and health sciences
0302 clinical medicine
Cerebrospinal fluid
Electroconvulsive therapy
Neurotrophic factors
Internal medicine
Outcome Assessment
Health Care
medicine
Humans
Pharmacology (medical)
Ictal
Neurogranin
ddc:610
Electroconvulsive Therapy
Klotho
Biological Psychiatry
Aged
Depressive Disorder
Major
business.industry
therapy [Depressive Disorder
Major]
Electromyography
Remission Induction
therapy [Depressive Disorder
Treatment-Resistant]
General Medicine
Middle Aged
cerebrospinal fluid [Depressive Disorder
Major]
030227 psychiatry
Psychiatry and Mental health
cerebrospinal fluid [Biomarkers]
cerebrospinal fluid [Bipolar Disorder]
Antidepressant
Female
business
therapy [Bipolar Disorder]
Biomarkers
030217 neurology & neurosurgery
Zdroj: European archives of psychiatry and clinical neuroscience 270(7), 911-919 (2019). doi:10.1007/s00406-019-01086-x
DOI: 10.1007/s00406-019-01086-x
Popis: For patients with depression treated with electroconvulsive therapy (ECT), the novel seizure quality index (SQI) can predict the risk of non-response (and non-remission)—as early as after the second ECT session—based the extent of several ictal parameters of the seizure. We aim to test several CSF markers on their ability to predict the degree of seizure quality, measured by the SQI to identify possible factors, that could explain some variability of the seizure quality. Baseline CSF levels of metabolites from the kynurenine pathway, markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system, endocannabinoids, sphingolipids, neurotrophic factors (VEGF) and Klotho were measured before ECT in patients with depression (n = 12) to identify possible correlations with the SQI by Pearson's partial correlation. Negative, linear relationships with the SQI for response were observed for CSF levels of T-tau (rpartial = − 0.69, p = 0.019), phosphatidylcholines (rpartial = − 0.52, p = 0.038) and IL-8 (rpartial = − 0.67, p = 0.047). Regarding the SQI for remission, a negative, linear relationship was noted with CSF levels of the endocannabinoid AEA (rpartial = − 0.70, p = 0.024) and CD163 (rpartial = − 0.68, p = 0.029). In sum, CSF Markers for the innate immune system, for neurodegeneration and from lipids were found to be associated with the SQI for response and remission after adjusting for age. Consistently, higher CSF levels of the markers were always associated with lower seizure quality. Based on these results, further research regarding the mechanism of seizure quality in ECT is suggested.
Databáze: OpenAIRE
Externí odkaz: